Ampiroxicam
Nasil · Flucam · CP 65703 · Ampiroam · AMPIROXICAM · Ampiroxicam 98% · Ampiroxicam(CP 65703) · Ampiroxicam USP/EP/BP
Identifikatoren & physikalische Daten
| CAS No. | 99464-64-9 |
|---|---|
| Summenformel | C20H21N3O7S |
| Durchschnittliche Molmasse | 447,5 g/mol |
| Monoisotopische Masse | 447,11002119 g/mol |
| SMILES | CCOC(=O)OC(C)OC1=C(C(=O)Nc2ccccn2)N(C)S(=O)(=O)c2ccccc21 |
| InChIKey | LSNWBKACGXCGAJ-UHFFFAOYSA-N |
| PubChem CID | 2176 |
| ChEMBL | CHEMBL1566249 |
| ChEBI | CHEBI:31210 |
| EC No. | 807-877-6 |
| DTXSID | DTXSID6046474 |
Chemische & physikalische Eigenschaften
| XLogP | 4 |
|---|---|
| Polarare Oberfläche (TPSA) | 133 |
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 9 |
| Frei drehbare Bindungen | 8 |
| Schwere Atome | 31 |
| Formalladung | 0 |
| Komplexität | 808 |
| Schmelzpunkt | 159-161C |
| Dichte | 1.44±0.1 g/cm3(Predicted) |
| Lagerbedingungen | Sealed in dry,2-8°C |
| Löslichkeit | Chloroform (Slightly), Methanol (Slightly) |
| Aggregatzustand | Solid |
| pKa (Säurekonstante) | 12.74±0.20(Predicted) |
| Farbe | White to Off-White |
| CAS Datenbank | 99464-64-9(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 4 (100%) |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)AmpiroxicamDILI PositiveDOI:10.1016/j.drudis.2019.09.022 |
| Toxizität | LD50 orally in male, female rats: 1798, 747 mg/kg (Iijima) |
Anwendungen & Verwendung
Beschreibung
Ampiroxicam is a once-daily non-steroidal anti-inflammatory drug (NSAID) introduced in Japan. As a non-acidic ether carbonate prodrug of the widely used antiinflammatory agent, piroxicam, ampiroxicam is similar or more potent than piroxicam in suppressing carrageenan edema, ultraviolet erythema, traumatic edema, capillary permeability, acetic acid writhing, yeast algesia and yeast hyperthermia in many animals. Eioavailability studies in man show undetectable plasma levels of ampiroxicam indicating 100% conversion to piroxicam during absorption process. Ampiroxicam has been reported to have fewer side effects on the gastric mucosa than piroxicam.
Verwenden
Prodrug of Piroxicam. Anti-inflammatory.